Signaling Gateway - 2 July 2009
http://links.ealert.nature.com/ctt?kn=54&m=33489807&r=MTc2ODc4NDI0MAS2&b=2&j=NTI0MzE3NDES1&mt=1&rt=0
*********************************************************************
Signaling Update is a one-stop online resource designed to keep you
in touch with the latest and most exciting research in cell
signaling. New content is uploaded every Friday.
http://links.ealert.nature.com/ctt?kn=48&m=33489807&r=MTc2ODc4NDI0MAS2&b=2&j=NTI0MzE3NDES1&mt=1&rt=0
*********************************************************************
In Signaling Update this week:
------------------------
Featured Article
------------------------
TGF-BETA SIGNALING: A NEW PIECE OF THE PUZZLE
TGF-beta signaling promotes the nuclear accumulation of CLIC4, which
mediates the transcriptional response to TGF-beta by protecting
phospho-Smad2 and 3 from dephosphorylation.
Original research paper: Nature Cell Biology 11, 777-784 2009
http://links.ealert.nature.com/ctt?kn=16&m=33489807&r=MTc2ODc4NDI0MAS2&b=2&j=NTI0MzE3NDES1&mt=1&rt=0
------------------------
Molecule Pages
------------------------
CHEMOKINE RECEPTOR CCR1
http://links.ealert.nature.com/ctt?kn=56&m=33489807&r=MTc2ODc4NDI0MAS2&b=2&j=NTI0MzE3NDES1&mt=1&rt=0
CCR1 was the first human CC chemokine receptor to be identified at
the cDNA level. Although CCR1 was initially described as a receptor
for the chemokines CCL3 and CCL5, a number of other chemokine ligands
have been described, some of which are generated from weak agonists
by proteases during inflammatory responses in vivo. Because CCR1
seems to have a role in host defense and inflammation, it represents
a potential target for therapeutic intervention in various clinically
important diseases.
Search the molecule pages
http://links.ealert.nature.com/ctt?kn=38&m=33489807&r=MTc2ODc4NDI0MAS2&b=2&j=NTI0MzE3NDES1&mt=1&rt=0
-------------------
Selected Updates
-------------------
PROTEIN DEGRADATION: ASSEMBLY FROM THE BASE
Multiple evolutionarily conserved chaperones generate specific
subcomplexes that are assembled into the 19S regulatory particle and
the 20S core particle to form the complete 26S proteasome.
Original research paper: Cell 137, 887-899 (2009)
http://links.ealert.nature.com/ctt?kn=53&m=33489807&r=MTc2ODc4NDI0MAS2&b=2&j=NTI0MzE3NDES1&mt=1&rt=0
THERAPEUTICS: DEPENDENT ON KRAS
A systems biology approach has enabled the identification of several
novel KRAS-dependent signaling pathways and proteins in cancer cell
lines.
Original research paper: Cell 137, 835-848 (2009)
http://links.ealert.nature.com/ctt?kn=4&m=33489807&r=MTc2ODc4NDI0MAS2&b=2&j=NTI0MzE3NDES1&mt=1&rt=0
ADDICTION: LET ME COUNT THE GENES
Chronic cocaine exposure increases deltaFosB-mediated transcription
of sirtuins 1 and 2, altering MAPK signaling in the nucleus
accumbens.
Original research paper: Neuron 62, 335-348 (2009)
http://links.ealert.nature.com/ctt?kn=40&m=33489807&r=MTc2ODc4NDI0MAS2&b=2&j=NTI0MzE3NDES1&mt=1&rt=0
More Updates:
http://links.ealert.nature.com/ctt?kn=52&m=33489807&r=MTc2ODc4NDI0MAS2&b=2&j=NTI0MzE3NDES1&mt=1&rt=0
------------------------
Research Library
------------------------
http://links.ealert.nature.com/ctt?kn=14&m=33489807&r=MTc2ODc4NDI0MAS2&b=2&j=NTI0MzE3NDES1&mt=1&rt=0
A PARALLEL CIRCUIT OF LIF SIGNALLING PATHWAYS MAINTAINS PLURIPOTENCY
OF MOUSE ES CELLS
Nature 459, 118-122 (2009)
http://links.ealert.nature.com/ctt?kn=26&m=33489807&r=MTc2ODc4NDI0MAS2&b=2&j=NTI0MzE3NDES1&mt=1&rt=0
TGF-[beta] ACTIVATES AKT KINASE THROUGH A MICRORNA-DEPENDENT
AMPLIFYING CIRCUIT TARGETING PTEN
Nature Cell Biology 11, 881-889 (2009)
http://links.ealert.nature.com/ctt?kn=25&m=33489807&r=MTc2ODc4NDI0MAS2&b=2&j=NTI0MzE3NDES1&mt=1&rt=0
REL, ENCODING A MEMBER OF THE NF-[kappa]B FAMILY OF TRANSCRIPTION
FACTORS, IS A NEWLY DEFINED RISK LOCUS FOR RHEUMATOID ARTHRITIS
Nature Genetics 41, 820-823 (2009)
http://links.ealert.nature.com/ctt?kn=46&m=33489807&r=MTc2ODc4NDI0MAS2&b=2&j=NTI0MzE3NDES1&mt=1&rt=0
------------------------
Signaling News
------------------------
NATURE COLLECTION: CANCER
http://links.ealert.nature.com/ctt?kn=9&m=33489807&r=MTc2ODc4NDI0MAS2&b=2&j=NTI0MzE3NDES1&mt=1&rt=0
The development of cancer is an evolutionary process that is driven
by multiple genetic and epigenetic changes. This free collection
contains a selection of recent papers published in Nature that yield
insights into the genetic and epigenetic basis of human cancers, the
biological processes that drive cancer progression and the efforts to
translate such findings into potential clinical applications.
More news
http://links.ealert.nature.com/ctt?kn=27&m=33489807&r=MTc2ODc4NDI0MAS2&b=2&j=NTI0MzE3NDES1&mt=1&rt=0
-------------------------
Gateway Updates
-------------------------
LIPIDOMICS GATEWAY - JULY UPDATE
http://links.ealert.nature.com/ctt?kn=20&m=33489807&r=MTc2ODc4NDI0MAS2&b=2&j=NTI0MzE3NDES1&mt=1&rt=0
The Lipidomics Gateway is a free, comprehensive website for
researchers interested in lipid biology.
This month's update features "Fat finding in disease: Lipids coming
'ome" and "Low-fat marrow: Good for the blood".
Sign up here to receive the monthly update alert for the
Lipidomics Gateway.
http://links.ealert.nature.com/ctt?kn=41&m=33489807&r=MTc2ODc4NDI0MAS2&b=2&j=NTI0MzE3NDES1&mt=1&rt=0
-----------------------------
Job of the Week
-----------------------------
Postdoctoral Position
Employer: University of Chicago
Location: Chicago, Illinois, USA
http://links.ealert.nature.com/ctt?kn=28&m=33489807&r=MTc2ODc4NDI0MAS2&b=2&j=NTI0MzE3NDES1&mt=1&rt=0
A postdoctoral position is available in the Division of Biological
Sciences at the University of Chicago. The successful applicant will
study tumor evasion and genesis regulatory pathways, focusing on a
subset of the TNF receptor family and the role of regulatory T cells
in this setting. The long-term goals for this project are to develop
therapeutic targets and cellular therapies in the field of stem-cell
transplantation.
More Jobs:
http://links.ealert.nature.com/ctt?kn=13&m=33489807&r=MTc2ODc4NDI0MAS2&b=2&j=NTI0MzE3NDES1&mt=1&rt=0
To advertise a job in this spot, please contact Naturejobs.
http://links.ealert.nature.com/ctt?kn=50&m=33489807&r=MTc2ODc4NDI0MAS2&b=2&j=NTI0MzE3NDES1&mt=1&rt=0
======================================================================
Genentech is proud to be a corporate sponsor of the UCSD-Nature Signaling Gateway.
Genentech is a leading biotechnology company that discovers,
develops, manufactures and commercializes biotherapeutics
for significant unmet medical needs. Fifteen of the currently
approved biotechnology products stem from or are based on
Genentech science. Genentech manufactures and commercializes
ten biotechnology products directly in the United States.
The company has headquarters in South San Francisco, California,
and is traded on the New York Stock Exchange under the symbol DNA.
http://links.ealert.nature.com/ctt?kn=5&m=33489807&r=MTc2ODc4NDI0MAS2&b=2&j=NTI0MzE3NDES1&mt=1&rt=0
=====================================================================
As a registered user of the Nature Publishing Group web sites, you
were selected to receive this message in the genuine belief that it
would be of interest to you.
If you no longer wish to receive news and announcements from Nature
Publishing Group or wish to unsubscribe from the Signaling Update
email alert please update your online Nature.com account details here:
http://links.ealert.nature.com/ctt?kn=39&m=33489807&r=MTc2ODc4NDI0MAS2&b=2&j=NTI0MzE3NDES1&mt=1&rt=0
For further technical assistance or any other enquiries, please click here:
http://links.ealert.nature.com/ctt?kn=35&m=33489807&r=MTc2ODc4NDI0MAS2&b=2&j=NTI0MzE3NDES1&mt=1&rt=0
Nature's world-wide offices:
London . Paris . Munich . New Delhi . Tokyo . Melbourne . San Diego .
San Francisco . Washington . New York . Boston
(c) 2009 Nature Publishing Group
---------------------------------------------------------------------
